Wilmer Eye Institute at Johns Hopkins Will Conduct Training For Sunrise LTK Procedure

Apr 10, 2001, 01:00 ET from Sunrise Technologies International, Inc.

    FREMONT, Calif., April 10 /PRNewswire/ --
 Sunrise Technologies International, Inc. (Nasdaq: SNRS) -- announced today
 that The Wilmer Eye Institute at Johns Hopkins University School of Medicine
 in Baltimore, MD, will conduct a training course that includes live surgery on
 Wednesday, April 11, 2001.
     The Wilmer Eye Institute, located in Baltimore, Maryland, is repeatedly
 ranked as the top eye care center in the nation by U.S. News and World Report
 and Ophthalmology Times.  Wilmer is the first, and thus far, the only center
 in Baltimore to offer LTK.
     "A comprehensive refractive surgeon is not limited to LASIK as the only
 surgical procedure. We think, that contrary to conventional wisdom, a
 refractive surgeon should perform more than LASIK.  Our cornea specialists at
 Wilmer strive for a level of diverse expertise that utilizes all advanced
 technologies," said Dr. Terrence O'Brien, Director of Refractive Surgery and
 Ocular Infections, Johns Hopkins Wilmer Laser Vision Center.
     The HYPERION(TM) LTK system reshapes the cornea in three seconds with no
 surgical incision.  It has an excellent safety profile and provides a unique
 alternative to LASIK to treat low to moderate hyperopia.
     The training course at Wilmer will include surgeons at the John Hopkins
 Center and other physicians in the immediate area.  Special instruction will
 be conducted by Dr. O'Brien and Mark Milner, M.D. of Hamden, Connecticut, also
 an experienced Sunrise LTK surgeon.
     "We are proud to be associated with Wilmer, one of the great teaching
 hospitals in the U.S.  We look forward to working closely with Dr. O'Brien and
 other cornea specialists at Wilmer in helping expand our technology and its
 ability to treat refractive error," said C. Russell Trenary III, Sunrise
 Chairman and Chief Executive Officer.
     The U.S. Food and Drug Administration approved the Company's HYPERION(TM)
 LTK System on June 30, 2000 for the temporary reduction of hyperopia in
 patients with +0.75 TO +2.50 diopters of MRSE with less than or equal to
 +/- 0.75 diopters of astigmatism, who are 40 years of age or older with
 documented stability of refraction for the prior 6 months, as demonstrated by
 a change of less than or equal to 0.50D in spherical and cylindrical
 components of the manifest refraction.  The magnitude of correction with this
 treatment diminishes over time, with some patients retaining some or all of
 their refractive correction.  The new labeling says that, based upon existing
 information for the clinical parameters used in the clinical trial, the
 Company's model for the average longevity for the procedure indicates that
 some of the effect lasts 10 years and beyond.  Age related drift towards
 hyperopia contributes to the loss of effect after the initial two years.
     Sunrise Technologies International, Inc. is a refractive surgery company
 based in Fremont, California, that has developed holmium:YAG laser-based
 systems that utilize a patented process for shrinking collagen developed by
 Dr. Bruce Sand (the "Sand Process") in correcting ophthalmic refractive
 conditions.
     Except for historical information, this news release contains certain
 forward-looking statements that involve risk and uncertainties, which may
 cause actual results to differ materially from the statements made including
 market potential, regulatory clearances, business growth, and other risks
 listed from time to time in the Company's Securities and Exchange Commission
 (SEC) filings. These forward-looking statements represent the Company's
 judgment, as of the date of this release, and the Company disclaims any intent
 or obligation to update these forward-looking statements.
     Internet users can access Sunrise's World Wide Web site at
 http://www.sunrise-tech.com .
 
 

SOURCE Sunrise Technologies International, Inc.
    FREMONT, Calif., April 10 /PRNewswire/ --
 Sunrise Technologies International, Inc. (Nasdaq: SNRS) -- announced today
 that The Wilmer Eye Institute at Johns Hopkins University School of Medicine
 in Baltimore, MD, will conduct a training course that includes live surgery on
 Wednesday, April 11, 2001.
     The Wilmer Eye Institute, located in Baltimore, Maryland, is repeatedly
 ranked as the top eye care center in the nation by U.S. News and World Report
 and Ophthalmology Times.  Wilmer is the first, and thus far, the only center
 in Baltimore to offer LTK.
     "A comprehensive refractive surgeon is not limited to LASIK as the only
 surgical procedure. We think, that contrary to conventional wisdom, a
 refractive surgeon should perform more than LASIK.  Our cornea specialists at
 Wilmer strive for a level of diverse expertise that utilizes all advanced
 technologies," said Dr. Terrence O'Brien, Director of Refractive Surgery and
 Ocular Infections, Johns Hopkins Wilmer Laser Vision Center.
     The HYPERION(TM) LTK system reshapes the cornea in three seconds with no
 surgical incision.  It has an excellent safety profile and provides a unique
 alternative to LASIK to treat low to moderate hyperopia.
     The training course at Wilmer will include surgeons at the John Hopkins
 Center and other physicians in the immediate area.  Special instruction will
 be conducted by Dr. O'Brien and Mark Milner, M.D. of Hamden, Connecticut, also
 an experienced Sunrise LTK surgeon.
     "We are proud to be associated with Wilmer, one of the great teaching
 hospitals in the U.S.  We look forward to working closely with Dr. O'Brien and
 other cornea specialists at Wilmer in helping expand our technology and its
 ability to treat refractive error," said C. Russell Trenary III, Sunrise
 Chairman and Chief Executive Officer.
     The U.S. Food and Drug Administration approved the Company's HYPERION(TM)
 LTK System on June 30, 2000 for the temporary reduction of hyperopia in
 patients with +0.75 TO +2.50 diopters of MRSE with less than or equal to
 +/- 0.75 diopters of astigmatism, who are 40 years of age or older with
 documented stability of refraction for the prior 6 months, as demonstrated by
 a change of less than or equal to 0.50D in spherical and cylindrical
 components of the manifest refraction.  The magnitude of correction with this
 treatment diminishes over time, with some patients retaining some or all of
 their refractive correction.  The new labeling says that, based upon existing
 information for the clinical parameters used in the clinical trial, the
 Company's model for the average longevity for the procedure indicates that
 some of the effect lasts 10 years and beyond.  Age related drift towards
 hyperopia contributes to the loss of effect after the initial two years.
     Sunrise Technologies International, Inc. is a refractive surgery company
 based in Fremont, California, that has developed holmium:YAG laser-based
 systems that utilize a patented process for shrinking collagen developed by
 Dr. Bruce Sand (the "Sand Process") in correcting ophthalmic refractive
 conditions.
     Except for historical information, this news release contains certain
 forward-looking statements that involve risk and uncertainties, which may
 cause actual results to differ materially from the statements made including
 market potential, regulatory clearances, business growth, and other risks
 listed from time to time in the Company's Securities and Exchange Commission
 (SEC) filings. These forward-looking statements represent the Company's
 judgment, as of the date of this release, and the Company disclaims any intent
 or obligation to update these forward-looking statements.
     Internet users can access Sunrise's World Wide Web site at
 http://www.sunrise-tech.com .
 
 SOURCE  Sunrise Technologies International, Inc.